Information Provided By: 
Fly News Breaks for January 4, 2016
FLML
Jan 4, 2016 | 07:02 EDT
SunTrust analyst John Boris recommends using Thursday's pullback in shares of Flamel Technologies after the FDA approved West-Ward's generic neostigmine as a buying opportunity. Flamel's value creation is driven by its proprietary drug delivery pipeline, Boris tells investors in a research note. He reiterates a Buy rating on the stock with a $33 price target.
News For FLML From the Last 2 Days
There are no results for your query FLML
